| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | 130.576 | 83.047 | 89.128 | 45.631 | 4.451 | 3.294 | 6.398 | 8.821 | 4.458 | 0 |
| Total Income - EUR | 130.886 | 120.943 | 89.208 | 49.929 | 4.455 | 3.297 | 6.400 | 8.822 | 4.458 | 0 |
| Total Expenses - EUR | 152.695 | 131.024 | 92.417 | 62.220 | 4.670 | 3.541 | 6.574 | 5.220 | 7.751 | 5.082 |
| Gross Profit/Loss - EUR | -21.810 | -10.081 | -3.209 | -12.291 | -215 | -245 | -174 | 3.602 | -3.293 | -5.082 |
| Net Profit/Loss - EUR | -21.810 | -12.559 | -4.028 | -12.815 | -349 | -337 | -362 | 3.342 | -3.293 | -5.082 |
| Employees | 7 | 3 | 3 | 2 | 0 | 0 | 0 | 0 | 0 | 0 |
Check the financial reports for the company - Pharmacon Srl
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | 68.627 | 42.638 | 41.916 | 41.147 | 40.350 | 40.999 | 37.785 | 36.867 | 35.723 | 34.496 |
| Current Assets | 26.726 | 28.760 | 29.929 | 8.217 | 8.994 | 8.454 | 8.143 | 7.648 | 4.915 | 4.037 |
| Inventories | 13.853 | 18.535 | 13.750 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Receivables | 10.819 | 1.003 | 15.350 | 5.732 | 4.495 | 5.173 | 5.412 | 6.031 | 3.098 | 3.601 |
| Cash | 2.054 | 9.222 | 828 | 2.485 | 4.499 | 3.281 | 2.730 | 1.617 | 1.817 | 436 |
| Shareholders Funds | 72.096 | 58.802 | 53.779 | 27.450 | 26.569 | 25.728 | 24.795 | 28.214 | 24.836 | 19.615 |
| Social Capital | 45 | 45 | 44 | 43 | 42 | 41 | 40 | 41 | 40 | 40 |
| Debts | 23.258 | 12.596 | 18.066 | 21.914 | 22.776 | 23.725 | 21.133 | 16.301 | 15.802 | 18.918 |
| Income in Advance | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "6820 - 6820" | |||||||||
| CAEN Financial Year |
4773
|
|||||||||
Comments - Pharmacon Srl